RxDoctor Payments Data

Charlotte Lindsey

Psychiatric/Mental Health · San Angelo, TXNPI 1326204405

Payments from drug & device makers

$820in general payments, 2019–2025

Across 40 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$163
  • Otsuka America Pharmaceutical, Inc.$117
  • Teva Pharmaceuticals USA, Inc.$110
  • Johnson & Johnson$108
  • AbbVie$101
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$69
  • plus $153 from 4 others

What the payments were for

  • Food & beverage$820100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$820 in reported general payments places this provider in the 55th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$10,113
Medicare patients
52
Services billed
98

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate28$225,274
Abilify MaintenaAripiprazole13$37,319
Invega SustennaPaliperidone Palmitate11$32,920
VraylarCariprazine Hcl18$26,924
Aripiprazole67$9,781
Clozapine92$6,574
Chlorpromazine Hcl22$3,488
Oxcarbazepine63$2,698
Trazodone Hcl166$2,180
Quetiapine Fumarate158$2,110
Buspirone Hcl109$1,759
Venlafaxine Hcl ErVenlafaxine Hcl90$1,397
Haloperidol36$1,299
Divalproex Sodium ErDivalproex Sodium31$1,234
Hydroxyzine Pamoate77$1,197

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$163$225,27428 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$117$37,31913 claims
Johnson & JohnsonInvega Sustenna$108$32,92011 claims
AbbVieVraylar$101$26,92418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in San Angelo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →